Senseonics: The Loss Widened. The Margins Didn't.

The headlines coming out of Senseonics' Q2 report will fixate on the $36.7 million net loss — more than double the $14.5 million loss from the same quarter last year. It looks like a business getting worse, not better. The operating numbers say the opposite.

Revenue jumped 120% year-over-year to $14.5 million, up from $11.7 million just last quarter. Gross margin — the percentage of each dollar of revenue that remains after the cost of producing and delivering the sensor — expanded to roughly 59%, up from 47% a year ago. For a company with a $256 million market cap that has been sliced nearly in half over the past twelve months, the margin expansion is the entire thesis. The widening loss is a transition cost, not a structural deterioration.

Here's what happened. Senseonics spent 2025 rebuilding its commercial engine after bringing the Eversense CGM (continuous glucose monitor) distribution rights back from Ascensia, its former global partner. The U.S. commercial team moved in-house on January 1, 2026. The European transition wrapped in June. Hiring a new sales force, absorbing former Ascensia personnel, and building out country-level operations in Germany, Italy, Spain, and Sweden is expensive. It front-loaded $32.9 million in SG&A for Q2, up from $9.7 million a year earlier. That's what blew out the loss.

The revenue side of the story is harder to dismiss. U.S. revenue grew more than 150% year-over-year to $12.6 million — the highest quarterly shipment volume in the company's history. Active prescribers increased roughly 130%. The Eon Care nurse-insertion network — a distributed network of nurses who travel to insert the implantable sensor, removing the need for a minor surgical procedure — now covers about 40% of insertions with over 90 nurses deployed. Management's year-end goal is 100. The product adoption curve is real, and it's self-reinforcing: more prescribers create more awareness, which drives more patient starts, which justifies further commercial investment.

Senseonics raised its full-year 2026 revenue guidance to $62–$66 million from $60–$64 million. Gross margin guidance moved up to 58–61% from 55–58%. This is the second consecutive quarter the company has exceeded its own margin outlook. The management team has committed to 70%+ gross margins at scale. That's not a pipe-dream target for a medical device business that eliminates revenue sharing with a distributor and controls its own commercial costs.

So what's the bridge? If you take the midpoint of raised guidance — $64 million in revenue at roughly 59% gross margin — that produces about $37.8 million in gross profit for the year. R&D is running around $11.6 million per quarter, or roughly $46 million annualized. Even if SG&A normalizes to $15 million per quarter once the European transition costs fade — a generous assumption that cuts Q2's $32.9 million roughly in half — the company will still operate in the red in 2026. The quarterly operating loss, however, should compress from the current $24+ million range to something closer to $6–8 million.

The real inflection is 2027. If revenue accelerates to $85–95 million and gross margins push toward the upper end of the 60% range, gross profit hits $51–57 million. Against roughly $60 million in total operating expenses (R&D plus normalized SG&A), the company edges toward breakeven on an operating basis. That's when free cash flow — which has burned $96.8 million over the trailing twelve months — flips.

That bridge requires revenue to keep accelerating and margins to hold. Both are plausible. The revenue side is supported by the expanding prescriber base, Eversense 365's unique positioning as the first one-year implantable CGM, and the transition of Europe into a dedicated commercial organization that should normalize in H2 and contribute roughly 20% of annual revenue. The margin side is structural: Senseonics is no longer sharing revenue with Ascensia, and its cost of goods is compressing as it scales manufacturing.

The cash position has been propped up, which matters. The company raised roughly $90 million in equity during Q2 and expanded its Hercules Capital credit facility to $140 million. As of June 30, cash and short-term investments totaled $143 million against $55.5 million in debt. That gives them runway. But the dilution is real — shares outstanding have grown, and the market cap of $256 million at $5.15 per share reflects a stock that has fallen 48% over the past year despite the operational improvement.

That's the misread. The market is anchoring to the widening loss and treating Senseonics like a cash-burning biotech that hasn't found its product-market fit. It has. The Eversense 365 is a differentiated product in a rapidly growing CGM category, and the adoption acceleration is visible in quarterly shipment numbers. The loss widened because the company hired its way to a real commercial organization. That's a one-time cost step, not a permanent operating reality.

The target, the timeframe, the tripwire

If the 2027 bridge holds — $85–95 million in revenue, 60%+ gross margins, operating loss narrowing to single digits — a forward revenue multiple of 4.5–5x is reasonable for a CGM company on a trajectory toward positive free cash flow. That puts the fair value range at $380–$475 million in market cap, or roughly $7.30–$9.10 per share. I'd center on $8.00 with a 15-month horizon, taking us through Q4 2027 when the margin and revenue trajectory should be clear enough for the broader market to re-rate the story.

The tripwire is $4.00. A break below that level would signal that the market has permanently written off the margin-expansion thesis. More importantly, the thesis invalidates operationally if gross margins fall back below 50% in consecutive quarters or if the company needs another dilutive capital raise before the middle of 2027. Either of those would mean the commercial integration is costing more than the revenue growth can justify.

AInvest's aggregate signal labels Senseonics a Buy, which is the sort of opaque consensus score that doesn't help much when the real question is whether one-time transition costs mask a genuine inflection. The numbers do that work instead. The margin expansion is the proof point. The loss is the distraction.

The risk is straightforward. Senseonics is still an unprofitable medical device company operating in a category dominated by Dexcom and Abbott, both of which have massive scale and payer relationships that Senseonics is only beginning to build. The Eversense 365's one-year implant is a genuine differentiator, but clinical preference doesn't automatically translate to market share when reimbursement is the real gatekeeper. If the company can't accelerate U.S. payer coverage or if Europe's in-house commercial team underperforms after the initial transition costs clear, the revenue growth rate could stall and the margin story becomes theoretical.

But sitting at $5.15, down from a 52-week high of $11.58, the market is pricing Senseonics as if the commercial transition is a disaster rather than the painful step it was always going to be. The setup is cleaner when the crowd is still reading the loss column. The question is whether the margin trajectory over the next two quarters confirms that the pain is ending.

Setup summary - Thesis: Margins are expanding structurally. The loss widened from one-time transition costs, not business deterioration. Revenue growth of 120% is real. - Target: $8.00 (15 months, through Q4 2027) - Tripwire: $4.00 share price, or gross margins falling back below 50% for two consecutive quarters - What must go right: SG&A normalizes below $20M/quarter by H2 2026. Revenue hits midpoint guidance. No additional dilutive capital raise before mid-2027.